All News

24 October 2012

Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug ConjugatesAntibodies

24 October 2012

Helix BioPharma Corp. Announces First Patient Enrolled and First Dose Administered in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47Antibodies

23 October 2012

Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with AbbottAntibodies

22 October 2012

New One-Year Phase 3 Study Results Show Anti-TNF SIMPONI Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative ColitisAntibodies

22 October 2012

Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA (Adalimumab) For Patients with Moderately to Severely Active Ulcerative ColitisAntibodies

18 October 2012

Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA TreatmentAntibodies

18 October 2012

XBiotech Announces Progress in Clinical Development of Treatment for PsoriasisAntibodies

17 October 2012

Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and OverAntibodies

17 October 2012

WILEX AG announces results of Phase III ARISER study with RENCAREX in clear cell renal cell carcinomaAntibodies

17 October 2012

Tolera Therapeutics closes Series B-3 financing, raises $5.5 million to submit Phase 3 Special Protocol Assessment for its immune targeting biologic drug in kidney transplantationAntibodies

15 October 2012

Lilly Announces Positive Results For Ramucirumab as Single Agent in Phase III Gastric Cancer TrialAntibodies

15 October 2012

Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture TrialAntibodies

12 October 2012

FAB’ENTECH launches a Phase I clinical trial in Singapore for its new product against H5N1 Avian InfluenzaAntibodies

12 October 2012

FDA Approves Expanded Indication for ACTEMRA in Rheumatoid ArthritisAntibodies

11 October 2012

TYSABRI (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MSAntibodies

10 October 2012

Actinium Pharmaceuticals Announces Presentation for Actimab-A, a Novel Targeted Immunotherapy for Acute Myeloid Leukemia at the 8th Annual Hematologic Malignancies 2012 ConferenceAntibodies

9 October 2012

Immunomedics Discovers Potential New Therapy for Graft-Versus-Host DiseaseAntibodies

9 October 2012

Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II DevelopmentAntibodies

9 October 2012

Data from Investigator-Initiated Phase 2 Study of Eculizumab (Soliris) in Patients with Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association (ANA) Annual MeetingAntibodies

9 October 2012

Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer’s Disease Cooperative Study (ADCS)Antibodies

8 October 2012

Journal of Clinical Oncology publishes Phase III results of ZALTRAP (aflibercept) VELOUR studyAntibodies

8 October 2012

Merus announces the full validation of its MeMo(R) transgenic mouse for common light chain human antibodiesAntibodies

4 October 2012

OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical DevelopmentAntibodies

4 October 2012

ABLYNX REPORTS EXCELLENT INTERIM RESULTS FROM PHASE I/II STUDY WITH ITS ANTI-IL-6R NANOBODY, ALX-0061, IN RHEUMATOID ARTHRITIS PATIENTSAntibodies

4 October 2012

XOMA Initiates Safety and Efficacy Study of Gevokizumab in Patients With Non-Infectious Uveitis Currently Controlled by Systemic TreatmentAntibodies

3 October 2012

Lpath Begins iSONEP Dosing in Nexus Phase 2 StudyAntibodies

3 October 2012

MERRIMACK PHARMACEUTICALS’ THERAPIES SHOW PROMISE IN CERTAIN ADVANCED BREAST, GASTRIC AND GYNECOLOGIC CANCERSAntibodies

1 October 2012

Novel Concept for Treatment of Hemophilia A Published in Nature MedicineAntibodies

1 October 2012

Abbott’s HUMIRA (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative ColitisAntibodies

1 October 2012

Lilly Releases Phase II Results for Monoclonal Antibody Ramucirumab in Lung CancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

TL1A Inhibitor Pipeline Review

TSLP Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective